investors

Press Releases
Date Title and Summary View
May 15, 2017 LOS ANGELES, May 15, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced financial results for the first quarter 2017 and a re-evaluation of its financing and development strategies for ICT-107, its patient-specific, dendritic cell-based immunotherapy for patients with newly diagnosed glioblast...
March 23, 2017 LOS ANGELES and HOUSTON, March 23, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) and Memgen, LLC ("Memgen") announce the signing of a non-binding letter of intent to exclusively negotiate the terms  to possibly establish an immuno-oncology strategic collaboration focused on conducting clinical trials com...
March 14, 2017 LOS ANGELES, March 14, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2016 filed with the Securities and Exchange Commission on March 9, 2017, the audited financial statements contained an audit...
March 9, 2017 LOS ANGELES, March 9, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced financial results for the fourth quarter and full year 2016 and provided a corporate update.  Anthony Gringeri, PhD, ImmunoCellular's President and Chief Executive Offic...
March 6, 2017 LOS ANGELES, March 6, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report fourth quarter and full year 2016 financial results on Thursday, March 9, 2017. The Company also plans to hold a conference call and webcast on that day at 5:00 pm ET to discuss the fourth quarter ...
March 6, 2017 LOS ANGELES, March 6, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT:IMUC) today provided an update on the Company's ICT-107 phase 3 registration trial in newly diagnosed glioblastoma, and announced advances in its Stem-to-T-cell Research program. ICT-107 Phase ...
December 14, 2016 LOS ANGELES, Dec. 14, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT:IMUC) announced today that the Board of Directors has appointed Anthony Gringeri, PhD, as Chief Executive Officer and a member of the Board of Directors. Dr. Gringeri has served as ImmunoCellular's Senior Vice President of Strategic Resources s...
November 21, 2016 LOS ANGELES, Nov. 21, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT:IMUC) announced the presentation of updated immune monitoring data from the phase 2 trial of ICT-107 in patients with newly diagnosed glioblastoma. Also presented were updated long-term survival data from the phase 1 trial of ICT-107. ICT-107 i...
November 16, 2016 LOS ANGELES, Nov. 16, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (NYSE MKT: IMUC) announced that at the Special Meeting of Stockholders held on November 14, 2016, ImmunoCellular's stockholders voted to approve a reverse stock split of the Company's issued and outstanding common stock. Upon effectivene...
November 10, 2016 LOS ANGELES, Nov. 10, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced financial results for the third quarter of 2016 and provided an update on its research and development activities.  Andrew Gengos, ImmunoCellular's Chief Executive Officer, commented: "During the third quarter...
1
... NextLast
Add to Briefcase = add release to Briefcase
Copyright 2017 by Immunocellular Therapeutics, Ltd.
All Rights Reserved